The anthelmintic agent levamisole has immunostimulant properties in patients with defective cell-mediated immune responses. We are assessing the drug in patients with breast cancer to see whether it can maintain surgically induced remission. One such patient developed a severe cutaneous necrotising vasculitis, which disappeared once the drug was withdrawn.
The anthelmintic agent levamisole has immunostimulant properties in patients with defective cell-mediated immune responses. We are assessing the drug in patients with breast cancer to see whether it can maintain surgically induced remission. One such patient developed a severe cutaneous necrotising vasculitis, which disappeared once the drug was withdrawn.
Case report
A 59-year-old woman had been receiving thrice-weekly levamisole 150 mg/day for three months, when in May 1975 she developed fever and a severe rash. Cutaneous necrotising vasculitis was diagnosed. Biopsy of one of the lesions showed intense neutrophil and eosinophil infiltration of the vessel wall with obliteration of the lumen. There were no other physical abnormalities, and no sign of the original disease was noted. She had not been taking any other drugs.
Haemoglobin was 13 g/dl and white cell count 3 0 x 109/1 (3000/mm3; 30 % segmented neutrophils, 8 0o eosinophils, 10 Po monocytes, 52°lymphocytes). Results of complement studies were within normal limits, and other immunological and biochemical values were normal. A bone-marrow aspirate showed a normal distribution of white and red cells but a moderate increase in eosinophils. A chest radiograph was normal.
Levamisole was discontinued and the patient given a short course of prednisone 40 mg daily. After two weeks the clinical picture returned to normal, and three months later the skin lesions showed no signs of recurrence and the white cell count was normal.
Comment
Levamisole-induced vasculitis has not been reported, despite wide use of the drug in various conditions, including malignant and rheumatic diseases.1-3 The pathogenesis of our patient's skin reaction is unknown, though histologically it was similar to an Arthus-type reaction, in which immune-complex formation or complement activation is usually implicated. We found no complement abnormalities in our patient, but the tests did not exclude a local type III reaction.
The peripheral blood neutropenia in our patient also implicates levamisole as the causal agent, since neutropenia and agranulocytosis are associated with levamisole treatment.3 The exact mechanism of this reaction is unknown, but the peripheral and central eosinophilia suggest a hypersensitivity reaction. Although we did not challenge the patient (for ethical reasons) we think that levamisole was the likely cause of the vasculitis. The results of management of "early" breast cancer will be improved only by systemic treatment, since the disease should be regarded as systemic in many patients at the time of initial treatment.' We report the preliminary results of a trial of oral adjuvant chemotherapy with two drugs in 202 patients over 18 months. The aims of the study were, firstly, to observe the incidence and degree of toxicity, which must be acceptable to patients and clinicians; and, secondly, to establish the ease of administration-that is, the treatment should be within the capability of any hospital in Britain.
Trial design and results
The regimen is on trial in 70 centres in the UK and Ireland. Women are treated as outpatients in either surgical or chemotherapy clinics. Primary treatment is at the discretion of the surgeon, who has the option of either simple mastectomy and "watch" policy or simple mastectomy and radiotherapy or radical mastectomy. Patients under 70 with histologically evident spread to lymph nodes and in stage I or II are randomly allocated to chemotherapy or no chemotherapy.
Two oral drugs were chosen to try to maximise acceptability to patients and clinicians while retaining the advantages of multiple-drug treatment.2 3 Melphalan 10 mg is given on five consecutive days together with methotrexate 15 mg on the first day. This is repeated every six weeks for two years and should be started within four weeks after surgery toxicity with the two agents have stimulated us to progress to a threedrug regimen of melphalan, methotrexate, and 5-fluorouracil in a further attempt to devise a treatment with high acceptability and low toxicity. The findings will be reported. Advancing the management of early breast cancer is so complex that progress can be made only by multicentre studies. Evidence on toxicity with the moderate drug regimen should encourage other clinicians to participate.
We thank all the clinicians in the trial for their help and support in this preliminary study.
The evolution of H2 (gastroselective histaminergic) receptor antagonists (burimamide, metiamide, cimetidine) as healing drugs has ushered in a new and unique approach to the therapeutics of peptic ulcer disease. Raised plasma prolactin concentrations have, however, recently been reported in all of six patients under treatment with cimetidine.1
We report here five cases where there was neither biochemical nor clinical evidence of hyperprolactinaemia after treatment with cimetidine.
Patients, methods, and results
Five male patients aged 30-55 years (mean age 43 6) were investigated (see table). All had received 200 mg of cimetidine thrice daily, with 400 mg every night. The serum prolactin concentration was measured by the supraregional assay service for south-east London. 
Serum prolactin concentrations in patients studied

Comment
Hyperprolactinaemia may lead to impotence, hypogonadism, and gynaecomastia in men and cause galactorrhoea or amenorrhoea in women. Delle Fave et all have reported significantly raised concentrations of plasma prolactin in six patients with various gastrointestinal conditions (duodenal ulcer, anastomotic ulcer, and Zollinger-Ellison syndrome) being treated with cimetidine. Of these, one patient had gynaecomastia and a young woman had galactorrhoea. Bateson et al2 have reported progressively increasing hyperprolactinaemia with sustained galactorrhoea in a middle-aged woman with an endoscopically confirmed peptic ulcer under treatment with cimetidine. This patient was also concurrently being treated with chlorpromazine and metoclopramide, both of which block dopaminergic receptors in the hypothalamus-while dopamine is related to prolactin inhibitory factor or may itself be this factor.3 These drugs may, therefore, have played a part in the developing hyperprolactinaemia.
Hall4 reported breast pain and gynaecomastia in two patients with the Zollinger-Ellison syndrome and peptic ulcer disease under treatment with cimetidine: in both cases the plasma prolactin concentration was found to be normal. Our patients had no evidence of mastitis or gynaecomastia, or a history of taking other drugs which might have interfered with prolactin secretion.3 Their serum prolactin concentrations were within normal limits except in one case, the longest treated, where it was just higher than the normal limit. Hence our findings agree with those of Hall.4
As yet we have insufficient and conflicting information to allow any evaluation of the association between hyperprolactinaemia and treatment with cimetidine.
We thank the supraregional assay service for south-east London for measuring serum prolactin concentrations in our patients.
1 Delle Fave, G F, et al, Lancet, 1977 Lancet, , 1, 1319 Bateson, M C, et al, Lancet, 1977, 2, 247. 3 Thorner, M 0, Lancet, 1975, 1, 662. Since Atkinson' first reported spontaneous rupture of the spleen in 1874 several cases have been described. The term "spontaneous rupture" has often been misleading, however, and Wright and Prigot' stated, "there is no such clinical entity as spontaneous rupture of the normal spleen." Johnson3 suggested that careful questioning of the patient and relatives will always elicit a history of injury. Nevertheless, as Orloff and Peskin4 pointed out, there are a few cases that even after careful scrutiny can only be instances of spontaneous rupture of the normal spleen. The following is apparently such a case, though there may be an explanation for the aetiology-namely, that it was a traction tear of the spleen caused by severe retching and vomiting.
Case history
A 72-year-old retired bank director presented in coma as an emergency case. He was pale, cold, sweating, and in obvious shock, with an unrecordable blood pressure and a rapid, thready pulse. He had been well until the
